Explore the FDA’s strategic move to classify Zika virus serological reagents as class II with special controls. This course details the regulatory implications, safety assurances, and potential benefits in patient access to diagnostic tools, providing learners with essential insights into the impact of this classification on the healthcare landscape.
In this course you will learn the following:
* Understand the classification process and criteria for Zika virus serological reagents.
* Identify the special controls and general controls applicable to these devices.
* Recognize the impact of this classification on regulatory burdens and patient access to innovative devices.
FDA’s Class II Classification of Zika Virus Serological Reagents
$9.99
1 year of access
Course Content
FDA’s Class II Classification of Zika Virus Serological Reagents
